Global Antibody-oligonucleotide Conjugates (AOCs) Market Research Report 2025

Publication ID:

PB504258861

Publication Date:

April 14, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

IT Services [2]

Hardware (Computing & Electronics) [3]

Computing & Electronics [4]

Description:

The global market for Antibody-oligonucleotide Conjugates (AOCs) was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ 1428 million by 2031, growing at a CAGR of 18.2% during the forecast period.
AOCs (Antibody-Oligonucleotide Conjugates) consist of three main components: a carrier (antibody), a linker, and a small nucleic acid. They allow for targeted delivery, combining the antibody鈥檚 ability to bind to specific cells with the gene-silencing capability of small nucleic acids, addressing the delivery challenges faced by conventional small nucleic acid drugs.
The development of Antibody-Oligonucleotide Conjugates (AOCs) aims to address the inherent limitations of small nucleic acids, such as poor serum stability, low membrane permeability, and lack of tissue selectivity. AOCs combine the longer half-life and precise targeting capabilities of antibodies with the gene-silencing power of small nucleic acids, achieving high-precision selectivity and effective delivery to target cells.
The global Antibody-oligonucleotide Conjugates (AOCs) market is experiencing explosive growth, with the core driving force coming from clinical breakthroughs in rare diseases (such as Duchenne muscular dystrophy and myotonic dystrophy) and innovative needs for targeted tumor therapy. Leading companies Avidity Biosciences (AOC 1001 clinical phase II) and Dyne Therapeutics (FORCE鈩� platform) are leading the race. On the technical side, pH-sensitive linkers optimize oligonucleotide release and bispecific antibody design improves tissue penetration, but low lysosomal escape efficiency (<10%) and high large-scale production costs (single dose exceeds US$50,000) are still the main bottlenecks. Regionally, North America accounts for more than 60% of the market share thanks to FDA accelerated approval and biotechnology clusters, while Asia Pacific relies on CDMO companies such as WuXi Biologics to enter the production link. In the next 3-5 years, with more than 20 AOC pipelines entering the clinic (indications expanding to ophthalmology and CNS) and AI-driven conjugation design (such as generative AI-optimized antibody-oligonucleotide pairing) being implemented, this field is expected to replicate the successful path of ADC drugs and become the next tens of billions of dollars market for precision medicine.
This report aims to provide a comprehensive presentation of the global market for Antibody-oligonucleotide Conjugates (AOCs), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody-oligonucleotide Conjugates (AOCs).
The Antibody-oligonucleotide Conjugates (AOCs) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antibody-oligonucleotide Conjugates (AOCs) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody-oligonucleotide Conjugates (AOCs) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Avidity Biosciences
Dyne Therapeutics
Tallac Therapeutics
Creative Biolabs
Abzena
BOCSCI Inc.
Wuxi AppTec
Lonza
Leinco
Segment by Type
Chemical Coupling
Enzymatic Coupling
Segment by Application
Pharmaceuticals
Scientific Research
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody-oligonucleotide Conjugates (AOCs) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Chemical Coupling
1.2.3 Enzymatic Coupling
1.3 Market by Application
1.3.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pharmaceuticals
1.3.3 Scientific Research
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Perspective (2020-2031)
2.2 Global Antibody-oligonucleotide Conjugates (AOCs) Growth Trends by Region
2.2.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Antibody-oligonucleotide Conjugates (AOCs) Historic Market Size by Region (2020-2025)
2.2.3 Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Region (2026-2031)
2.3 Antibody-oligonucleotide Conjugates (AOCs) Market Dynamics
2.3.1 Antibody-oligonucleotide Conjugates (AOCs) Industry Trends
2.3.2 Antibody-oligonucleotide Conjugates (AOCs) Market Drivers
2.3.3 Antibody-oligonucleotide Conjugates (AOCs) Market Challenges
2.3.4 Antibody-oligonucleotide Conjugates (AOCs) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antibody-oligonucleotide Conjugates (AOCs) Players by Revenue
3.1.1 Global Top Antibody-oligonucleotide Conjugates (AOCs) Players by Revenue (2020-2025)
3.1.2 Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Players (2020-2025)
3.2 Global Top Antibody-oligonucleotide Conjugates (AOCs) Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Antibody-oligonucleotide Conjugates (AOCs) Revenue
3.4 Global Antibody-oligonucleotide Conjugates (AOCs) Market Concentration Ratio
3.4.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody-oligonucleotide Conjugates (AOCs) Revenue in 2024
3.5 Global Key Players of Antibody-oligonucleotide Conjugates (AOCs) Head office and Area Served
3.6 Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Product and Application
3.7 Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Antibody-oligonucleotide Conjugates (AOCs) Breakdown Data by Type
4.1 Global Antibody-oligonucleotide Conjugates (AOCs) Historic Market Size by Type (2020-2025)
4.2 Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Type (2026-2031)
5 Antibody-oligonucleotide Conjugates (AOCs) Breakdown Data by Application
5.1 Global Antibody-oligonucleotide Conjugates (AOCs) Historic Market Size by Application (2020-2025)
5.2 Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
6.2 North America Antibody-oligonucleotide Conjugates (AOCs) Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025)
6.4 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
7.2 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025)
7.4 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
8.2 Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2020-2025)
8.4 Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
9.2 Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025)
9.4 Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
10.2 Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025)
10.4 Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Avidity Biosciences
11.1.1 Avidity Biosciences Company Details
11.1.2 Avidity Biosciences Business Overview
11.1.3 Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Introduction
11.1.4 Avidity Biosciences Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
11.1.5 Avidity Biosciences Recent Development
11.2 Dyne Therapeutics
11.2.1 Dyne Therapeutics Company Details
11.2.2 Dyne Therapeutics Business Overview
11.2.3 Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Introduction
11.2.4 Dyne Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
11.2.5 Dyne Therapeutics Recent Development
11.3 Tallac Therapeutics
11.3.1 Tallac Therapeutics Company Details
11.3.2 Tallac Therapeutics Business Overview
11.3.3 Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Introduction
11.3.4 Tallac Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
11.3.5 Tallac Therapeutics Recent Development
11.4 Creative Biolabs
11.4.1 Creative Biolabs Company Details
11.4.2 Creative Biolabs Business Overview
11.4.3 Creative Biolabs Antibody-oligonucleotide Conjugates (AOCs) Introduction
11.4.4 Creative Biolabs Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
11.4.5 Creative Biolabs Recent Development
11.5 Abzena
11.5.1 Abzena Company Details
11.5.2 Abzena Business Overview
11.5.3 Abzena Antibody-oligonucleotide Conjugates (AOCs) Introduction
11.5.4 Abzena Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
11.5.5 Abzena Recent Development
11.6 BOCSCI Inc.
11.6.1 BOCSCI Inc. Company Details
11.6.2 BOCSCI Inc. Business Overview
11.6.3 BOCSCI Inc. Antibody-oligonucleotide Conjugates (AOCs) Introduction
11.6.4 BOCSCI Inc. Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
11.6.5 BOCSCI Inc. Recent Development
11.7 Wuxi AppTec
11.7.1 Wuxi AppTec Company Details
11.7.2 Wuxi AppTec Business Overview
11.7.3 Wuxi AppTec Antibody-oligonucleotide Conjugates (AOCs) Introduction
11.7.4 Wuxi AppTec Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
11.7.5 Wuxi AppTec Recent Development
11.8 Lonza
11.8.1 Lonza Company Details
11.8.2 Lonza Business Overview
11.8.3 Lonza Antibody-oligonucleotide Conjugates (AOCs) Introduction
11.8.4 Lonza Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
11.8.5 Lonza Recent Development
11.9 Leinco
11.9.1 Leinco Company Details
11.9.2 Leinco Business Overview
11.9.3 Leinco Antibody-oligonucleotide Conjugates (AOCs) Introduction
11.9.4 Leinco Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
11.9.5 Leinco Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Avidity Biosciences
Dyne Therapeutics
Tallac Therapeutics
Creative Biolabs
Abzena
BOCSCI Inc.
Wuxi AppTec
Lonza
Leinco

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂